ArticleCureus2025
A Prospective Assessment of the Vesical Imaging Reporting and Data System in the Diagnosis of Muscle-Invasive Bladder Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergy of PET and MR imaging in the local and regional staging of bladder cancer.Therapeutic advances in urologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Worldwide, bladder cancer is one of the more common types of cancer. This study was conducted to evaluate the Vesical Imaging Reporting and Data System (VI-RADS) score for the diagnosis of muscle-invasive bladder cancer (MIBC). Additionally, the VI-RADS scores were compared with various relevant parameters and cancer stages. Materials and methods A prospective observational study design was used. The study was carried out in the Urology Department of the Indira Gandhi Institute of Medical Sciences (IGIMS) in Patna, India. It was conducted over a period of one and a half years, i.e., from December 2022 to July 2024. Overall, 71 patients were enrolled in the study. Results With a cut-off score of ≥3 for T2 (muscle-invasive), sensitivity and specificity were 93.75% (79.19% to 99.23%) and 76.92% (60.67% to 88.87%), respectively. With a cut-off score of VI-RADS ≥4 for muscle invasion, sensitivity and specificity were 62.5% (43.69% to 78.90%) and 89.74% (75.78% to 97.13%), respectively. VI-RADS scores of 1 and 2 were fairly accurate for non-muscle invasion, while scores of 4 and 5 were highly predictive of muscle invasion. A VI-RADS score of 3 remained the grey zone. Conclusion It is easy to interpret the VI-RADS score and assess detrusor muscle invasion. The present study on VI-RADS shows reliability for local staging and for differentiating non-MIBC (NMIBC) and MIBC. Among the VI-RADS scores, it was found that the result was statistically significant between high-grade and low-grade cancer, with a p-value <0.001.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.